Download PDF
Endoscopy 2020; 52(03): 186-192
DOI: 10.1055/a-1065-1759
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Endoscopic ultrasound and fine-needle aspiration for the detection of residual nodal disease after neoadjuvant chemoradiotherapy for esophageal cancer

Ruben D. van der Bogt
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
,
Berend J. van der Wilk
2   Department of Surgery, Erasmus MC University Medical Center, Rotterdam, the Netherlands
,
Jan-Werner Poley
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
,
Kausilia K. Krishnadath
3   Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands
,
Erik J. Schoon
4   Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, the Netherlands
,
Liekele E. Oostenbrug
5   Department of Gastroenterology and Hepatology, Zuyderland Medical Center, Heerlen, the Netherlands
,
Peter D. Siersema
6   Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands
,
Frank P. Vleggaar
7   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands
,
Marco J. Bruno
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
,
Katharina Biermann
8   Department of Pathology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
,
J. Jan B. van Lanschot
2   Department of Surgery, Erasmus MC University Medical Center, Rotterdam, the Netherlands
,
Manon C. W. Spaander
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
› Author AffiliationsSupported by: The Dutch Cancer Foundation EMCR 2014-7430
Further Information

Publication History

submitted 29 April 2019

accepted after revision 04 November 2019

Publication Date:
09 December 2019 (online)

Also available at
    Permissions and Reprints

Referred to by:

Endosonography-guided fine-needle aspiration for re-evaluation of lymph node status after neoadjuvant therapy in patients with esophageal cancer: is there any role for it?Endoscopy 2020; 52(03): 164-165
DOI: 10.1055/a-1095-3597

See also:

Reply to Rizzatti et al.Endoscopy 2020; 52(04): 317-317
DOI: 10.1055/a-1114-2608

See also:

Lymph node staging in esophageal/junctional tumors after chemoradiotherapy: should we change strategy?Endoscopy 2020; 52(04): 316-316
DOI: 10.1055/a-1103-1977

Abstract

Background Endoscopic ultrasound (EUS) and fine-needle aspiration (FNA) are potential tools for the detection of residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer. This study investigated yield of EUS and FNA for detection of malignant lymph nodes (LNs) after nCRT.

Methods This was a post hoc analysis of the preSANO trial. EUS was performed 10 – 12 weeks after nCRT. 18F-fluorodeoxyglucose positron emission tomography – computed tomography (18F-FDG PET-CT) was used to guide targeting of suspicious LNs. Consecutive FNA sampling was performed for suspicious LNs identified on EUS and/or PET-CT. EUS nodal staging was compared with histopathological examination of the resection specimen. The primary outcome was the proportion of correctly identified patients with malignant LNs by radial EUS.

Results 101 consecutive patients were included: 79 patients had no malignant LNs, of whom 62 were classified correctly by EUS (specificity 78 %); 22 patients had malignant LNs, of whom 11 were identified (sensitivity 50 %). Six of these patients had ≥ 1 suspicious LN not fulfilling EUS criteria (round, hypoechogenic, > 5 mm). Malignant LNs in falsely negative patients were predominantly located at distal LN stations. Specificity and sensitivity of conclusive FNA outcomes were 100 % (7/7) and 75 % (3/4), respectively. FNA outcome was uncertain in eight patients, half of whom appeared to have malignant LNs.

Conclusions EUS only detected 50 % of patients with malignant LNs 10 – 12 weeks after nCRT. To optimize sensitivity and minimize the risk of missing residual disease, FNA of LNs should be performed even in cases of low endosonographic suspicion.

Table 1s – 3s

 

  • References

  • 1 van Hagen P, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
    CrossrefPubMedSearch in Google Scholar
  • 2 Shapiro J, van Lanschot JJB, Hulshof M. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16: 1090-1098
    CrossrefPubMedSearch in Google Scholar
  • 3 Noordman BJ, Spaander MCW, Valkema R. et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 2018; 19: 965-974
    CrossrefPubMedSearch in Google Scholar
  • 4 Noordman BJ, Shapiro J, Spaander MC. et al. Accuracy of detecting residual disease after cross neoadjuvant chemoradiotherapy for esophageal cancer (preSANO Trial): rationale and protocol. JMIR Res Protoc 2015; 4: e79
    CrossrefPubMedSearch in Google Scholar
  • 5 van der Wilk BJ, Eyck BM, Spaander MCW. et al. Towards an organ-sparing approach for locally advanced esophageal cancer. Dig Surg 2019; 36: 462-469
    CrossrefPubMedSearch in Google Scholar
  • 6 Noordman BJ, Wijnhoven BPL, Lagarde SM. et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer 2018; 18: 142
    CrossrefPubMedSearch in Google Scholar
  • 7 ClinicalTrials.gov. Comparison of systematic surgery versus surveillance and rescue surgery in operable oesophageal cancer with a complete clinical response to radiochemotherapy. In: https://ClinicalTrials.gov/show/NCT02551458
    PubMed
  • 8 van der Bogt RD, Noordman BJ, Krishnadath KK. et al. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. Endoscopy 2019; 51: 326-332
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Valkema MJ, Noordman BJ, Wijnhoven BPL. et al. Accuracy of (18)F-FDG PET/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. J Nucl Med 2019; 60: 1553-1559
    CrossrefPubMedSearch in Google Scholar
  • 10 Dumonceau JM, Deprez PH, Jenssen C. et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated January 2017. Endoscopy 2017; 49: 695-714
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Bohle W, Kasper M, Zoller WG. Different accuracy of endosonographic tumor staging after neoadjuvant chemotherapy and chemoradiotherapy in esophageal cancer. Surg Endosc 2016; 30: 2922-2928
    CrossrefPubMedSearch in Google Scholar
  • 12 Bowrey DJ, Clark GW, Roberts SA. et al. Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus. J Gastrointest Surg 1999; 3: 462-467
    CrossrefPubMedSearch in Google Scholar
  • 13 Zuccaro Jr G, Rice TW, Goldblum J. et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999; 94: 906-912
    CrossrefPubMedSearch in Google Scholar
  • 14 van Rossum PS, Goense L, Meziani J. et al. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis. Gastrointest Endosc 2016; 83: 866-879
    CrossrefPubMedSearch in Google Scholar
  • 15 Sun F, Chen T, Han J. et al. Staging accuracy of endoscopic ultrasound for esophageal cancer after neoadjuvant chemotherapy: a meta-analysis and systematic review. Dis Esophagus 2015; 28: 757-771
    CrossrefPubMedSearch in Google Scholar
  • 16 Eyck BM, Onstenk BD, Noordman BJ. et al. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Ann Surg 2019;
    CrossrefPubMedSearch in Google Scholar
  • 17 Bhutani MS, Hawes RH, Hoffman BJ. A comparison of the accuracy of echo features during endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration for diagnosis of malignant lymph node invasion. Gastrointest Endosc 1997; 45: 474-479
    CrossrefPubMedSearch in Google Scholar
  • 18 Catalano MF, Sivak Jr MV, Rice T. et al. Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc 1994; 40: 442-446
    CrossrefPubMedSearch in Google Scholar
  • 19 Sobin LH, Gospodarowicz MK, Wittekind C. et al. TNM classification of malignant tumours. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell; 2010
    Search in Google Scholar
  • 20 Polkowski M, Jenssen C, Kaye P. et al. Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline – March 2017. Endoscopy 2017; 49: 989-1006
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Chirieac LR, Swisher SG, Ajani JA. et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103: 1347-1355
    CrossrefPubMedSearch in Google Scholar
  • 22 Edge S, Byrd DR, Compton CC. et al. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer-Verlag; 2010
    Search in Google Scholar
  • 23 Willis J, Cooper GS, Isenberg G. et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 2002; 55: 655-661
    CrossrefPubMedSearch in Google Scholar
  • 24 Griffin JM, Reed CE, Denlinger CE. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer. Ann Thorac Surg 2012; 93: 1855-1859 ; discussion 1860
    CrossrefPubMedSearch in Google Scholar
  • 25 Grotenhuis BA, Wijnhoven BP, Poley JW. et al. Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction. World J Surg 2013; 37: 147-155
    CrossrefPubMedSearch in Google Scholar
  • 26 Eloubeidi MA, Cerfolio RJ, Bryant AS. et al. Efficacy of endoscopic ultrasound in patients with esophageal cancer predicted to have N0 disease. Eur J Cardiothorac Surg 2011; 40: 636-641
    PubMedSearch in Google Scholar
  • 27 Agarwal B, Swisher S, Ajani J. et al. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol 2004; 99: 1258-1266
    CrossrefPubMedSearch in Google Scholar
  • 28 Kalha I, Kaw M, Fukami N. et al. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer 2004; 101: 940-947
    CrossrefPubMedSearch in Google Scholar
  • 29 Tong DK, Law S, Kwong DL. et al. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol 2010; 17: 2184-2192
    CrossrefPubMedSearch in Google Scholar
  • 30 Blackham AU, Yue B, Almhanna K. et al. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol 2015; 112: 597-602
    CrossrefPubMedSearch in Google Scholar
  • 31 Shapiro J, ten Kate FJ, van Hagen P. et al. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann Surg 2013; 258: 678-689
    CrossrefPubMedSearch in Google Scholar